Skip to content

Covid-19 Epidemic on Acute Stroke Management

Impact of th Covid-19 Epidemic on Acute Stroke Management

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04370197
Acronym
Stroke-Covid19
Enrollment
300
Registered
2020-04-30
Start date
2020-03-03
Completion date
2020-04-30
Last updated
2020-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Acute

Keywords

STROKE , Acute, Covid-19, SARS-COV-2, Mechanical thrombectomy, Thrombolysis

Brief summary

The Covid-19 pandemic is a pandemic of an emerging infectious disease, coronavirus 2019 (Covid-19), caused by the coronavirus SARS-CoV-2. It appears in November 2019 in the city of Wuhan, China, and spreads worldwide from February 2020. The first cases of infection in France were confirmed on 24 January 2020. As of April 14, 103,573 cases of infection were confirmed, 32,292 hospitalized cases, including 6,730 in intensive care, with 15,729 deaths recorded1. The most affected regions are Ile de France and the Grand Est (in particular the Haut-Rhin department). Containment of the entire French population was introduced on 17 March, with the aim of reducing the spread of the virus and relieving the burden on the health system, particularly the intensive care units. This unprecedented health crisis, as well as the social containment measures in themselves, has repercussions on other acute medical pthologies, not directly related to the viral infection. It appears that the number of patients treated for acute stroke has suddenly declined since the beginning of the epidemic. However, it is not clear whether it is the incidence of stroke that has declined or simply the proportion of patients presenting within the time frame that allows for treatment in the acute phase (by thrombolysis or thrombectomy).

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient * Stroke Patients * Patient who agreed to participate in this study

Exclusion criteria

\- Refusal to participate in this study

Design outcomes

Primary

MeasureTime frame
Study of the effect of pandemic covid-19 on the management of stroke patients1 month

Countries

France

Contacts

Primary ContactRémy BEAUJEUX, MD, PhD
remy.beaujeux@chru-strasbourg.fr33 3 88 12 78 71
Backup ContactSaïd CHAYER, PhD, HDR
said.chayer@chru-strasbourg.fr33 3 88 11 66 90

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026